Zealand Pharma A/S has significantly enhanced its capabilities in interactions with the medical community with the appointments of Dr. Danilo Verge and Dr. David Kendall to spearhead its Medical Affairs organization. As Head of Global Medical Affairs at Zealand Pharma, Dr. Danilo Verge will be responsible for all medical activities worldwide related to Zealand Pharma’s metabolic and gastrointestinal franchises including dasiglucagon, glepaglutide and V-Go. He brings over 20 years of experience from having built and led Medical Affairs functions. Dr. Verge has worked both in Europe and seven years in the US at Novo Nordisk and most recently Astra Zeneca, where he built the CV, Renal and Metabolic Global Medical Affairs function. Dr. David Kendall has taken up the position as Senior Global Medical Advisor Metabolism. In this capacity, Dr. Kendall will be responsible for designing and managing the implementation of the Medical product strategy and plan in the Metabolism Therapy Area, as well as representing Zealand Pharma at relevant scientific and medical fora, among other tasks. Dr. Kendall has more than 35 years of experience in diabetes research, clinical care, education, and pharmaceutical science. For most of the past 15 years he has held a series of leadership positions in the pharmaceutical sector including roles as Chief Medical Officer (MannKind Corporation), Vice President and Distinguished Medical Fellow (Eli Lilly and Co) and Executive Director, Medical Affairs (Amylin Pharmaceuticals Inc).